Sermorelin vs ipamorelin: which is legal to prescribe, and what is the difference?
Sermorelin and ipamorelin are both “growth hormone secretagogues”: they prompt the pituitary gland to release your own growth hormone rather than supplying growth hormone directly. They work through different receptors and have very different regulatory status.
Sermorelin
- A fragment of growth-hormone-releasing hormone (GHRH).
- Was once approved by FDA as a brand-name drug (Geref); the brand was discontinued for commercial reasons rather than safety.
- Commonly prescribed through licensed compounding pharmacies today. Compounded sermorelin is not FDA-approved.
- Evidence for anti-aging benefits in healthy adults is modest and largely older.
Ipamorelin
- Acts on the ghrelin receptor rather than the GHRH receptor.
- FDA has listed ipamorelin among bulk substances that raise significant safety concerns for compounding, which means licensed pharmacies generally cannot compound it.
- Products sold online as “research use only” are unapproved drugs. We do not sell or link to them.
Which is “better”?
There is no good head-to-head evidence in healthy people. In practice, the question is mostly settled by legality: sermorelin is the one a clinician can typically prescribe through a licensed pharmacy right now.
Before considering either
Sleep, resistance training, protein adequacy, and body-fat reduction all raise natural growth hormone output and carry far stronger evidence. See our longevity guide.
Safety information
Compounded peptides are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or quality. Only a licensed clinician can decide whether one is appropriate for you.
Sources
- fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- pubmed.ncbi.nlm.nih.gov/?term=sermorelin+growth+hormone+releasing+hormone
Read next
-
Is BPC-157 legal in the U.S.? Status as of October 2026
BPC-157 is not available by prescription, FDA sent warning letters to online sellers in August 2026, and an advisory panel has recommended a change. Here is where it stands.
-
Peptides for inflammation: what a clinician can actually prescribe in 2026
BPC-157 and TB-500 are not available by prescription today. Here is what is, what the evidence looks like, and the anti-inflammatory foundations that outperform them.